Advances in Treatment of Diffuse Midline Gliomas.
DIPG
Diffuse midline glioma
Pediatric oncology
Journal
Current neurology and neuroscience reports
ISSN: 1534-6293
Titre abrégé: Curr Neurol Neurosci Rep
Pays: United States
ID NLM: 100931790
Informations de publication
Date de publication:
03 Nov 2023
03 Nov 2023
Historique:
accepted:
16
10
2023
medline:
3
11
2023
pubmed:
3
11
2023
entrez:
3
11
2023
Statut:
aheadofprint
Résumé
Diffuse midline gliomas (DMGs) generally carry a poor prognosis, occur during childhood, and involve midline structures of the central nervous system, including the thalamus, pons, and spinal cord. To date, irradiation has been shown to be the only beneficial treatment for DMG. Various genetic modifications have been shown to play a role in the pathogenesis of this disease. Current treatment strategies span targeting epigenetic dysregulation, cell cycle, specific genetic alterations, and the immune microenvironment. Herein, we review the complex features of this disease as it relates to current and past therapeutic approaches.
Identifiants
pubmed: 37921944
doi: 10.1007/s11910-023-01317-8
pii: 10.1007/s11910-023-01317-8
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Di Ruscio V, Del Baldo G, Fabozzi F, Vinci M, Cacchione A, de Billy E, et al. Pediatric diffuse midline gliomas: an unfinished puzzle. Diagnostics (Basel). 2022;12(9):2064. https://doi.org/10.3390/diagnostics12092064 .
Buczkowicz P, Bartels U, Bouffet E, Becher O, Hawkins C. Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications. Acta Neuropathol. 2014;128(4):573–81.
pubmed: 25047029
pmcid: 4159563
doi: 10.1007/s00401-014-1319-6
Cohen KJ, Jabado N, Grill J. Diffuse intrinsic pontine gliomas-current management and new biologic insights. Is there a glimmer of hope? Neuro Oncol. 2017;19(8):1025–34.
pubmed: 28371920
pmcid: 5570259
doi: 10.1093/neuonc/nox021
Karremann M, Gielen GH, Hoffmann M, Wiese M, Colditz N, Warmuth-Metz M, et al. Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location. Neuro Oncol. 2018;20(1):123–31.
pubmed: 29016894
doi: 10.1093/neuonc/nox149
Vitanza NA, Cho YJ. Advances in the biology and treatment of pediatric central nervous system tumors. Curr Opin Pediatr. 2016;28(1):34–9.
pubmed: 26709691
doi: 10.1097/MOP.0000000000000309
Caretti V, Bugiani M, Freret M, Schellen P, Jansen M, van Vuurden D, et al. Subventricular spread of diffuse intrinsic pontine glioma. Acta Neuropathol. 2014;128(4):605–7.
pubmed: 24929912
pmcid: 4161623
doi: 10.1007/s00401-014-1307-x
Benesch M, Wagner S, Berthold F, Wolff JE. Primary dissemination of high-grade gliomas in children: experiences from four studies of the Pediatric Oncology and Hematology Society of the German Language Group (GPOH). J Neurooncol. 2005;72(2):179–83.
pubmed: 15925999
doi: 10.1007/s11060-004-3546-5
Wagner S, Benesch M, Berthold F, Gnekow AK, Rutkowski S, Sträter R, et al. Secondary dissemination in children with high-grade malignant gliomas and diffuse intrinsic pontine gliomas. Br J Cancer. 2006;95(8):991–7.
pubmed: 17047647
pmcid: 2360717
doi: 10.1038/sj.bjc.6603402
Vallero SG, Bertero L, Morana G, Sciortino P, Bertin D, Mussano A, et al. Pediatric diffuse midline glioma H3K27- altered: a complex clinical and biological landscape behind a neatly defined tumor type. Front Oncol. 2022;12:1082062.
pubmed: 36727064
doi: 10.3389/fonc.2022.1082062
Mondal G, Lee JC, Ravindranathan A, Villanueva-Meyer JE, Tran QT, Allen SJ, et al. Pediatric bithalamic gliomas have a distinct epigenetic signature and frequent EGFR exon 20 insertions resulting in potential sensitivity to targeted kinase inhibition. Acta Neuropathol. 2020;139(6):1071–88.
pubmed: 32303840
pmcid: 7792550
doi: 10.1007/s00401-020-02155-5
Sievers P, Sill M, Schrimpf D, Stichel D, Reuss DE, Sturm D, et al. A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of EGFR. Neuro Oncol. 2021;23(1):34–43.
pubmed: 33130881
doi: 10.1093/neuonc/noaa251
Buczkowicz P, Hawkins C. Pathology, molecular genetics, and epigenetics of diffuse intrinsic pontine glioma. Front Oncol. 2015;5:147.
pubmed: 26175967
pmcid: 4485076
doi: 10.3389/fonc.2015.00147
Puget S, Philippe C, Bax DA, Job B, Varlet P, Junier MP, et al. Mesenchymal transition and PDGFRA amplification/mutation are key distinct oncogenic events in pediatric diffuse intrinsic pontine gliomas. PloS One. 2012;7(2):e30313.
pubmed: 22389665
pmcid: 3289615
doi: 10.1371/journal.pone.0030313
Paugh BS, Broniscer A, Qu C, Miller CP, Zhang J, Tatevossian RG, et al. Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol. 2011;29(30):3999–4006.
pubmed: 21931021
pmcid: 3209696
doi: 10.1200/JCO.2011.35.5677
Edwards M, Wara W, Urtasun R, Prados M, Levin V, Fulton D, et al. Hyperfractionated radiation therapy for brain-stem glioma: a phase I-II trial. J Neurosurg. 1989;70:691–700.
pubmed: 2709109
doi: 10.3171/jns.1989.70.5.0691
Freeman C, Krischer J, Sanford R, Cohen M, Burger P, Del Carpio R, et al. Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children: a Pediatric Oncology Group study. Int J Radiat Oncol Biol Phys. 1993;27:197–206.
pubmed: 8407392
doi: 10.1016/0360-3016(93)90228-N
Packer R, Boyett J, Zimmerman R, Rorke L, Kaplan A, Albright A, et al. Hyperfractionated radiation therapy (72 Gy) for children with brain stem glioma: a Children’s Cancer Group Phase I/II Trial. Cancer. 1993;72:1414–21.
pubmed: 8339232
doi: 10.1002/1097-0142(19930815)72:4<1414::AID-CNCR2820720442>3.0.CO;2-C
Veldhuijzen van Zanten SEM, El-Khouly FE, Jansen MHA, Bakker DP, Sanchez Aliaga E, Haasbeek CJA, et al. A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma. J Neurooncol. 2017;135(2):307–15.
pubmed: 28748343
pmcid: 5663796
doi: 10.1007/s11060-017-2575-9
Carruthers R, Chalmers AJ. The potential of PARP inhibitors in neuro-oncology. CNS Oncol. 2012;1(1):85–97.
pubmed: 25054302
pmcid: 6176825
doi: 10.2217/cns.12.13
Chornenkyy Y, Agnihotri S, Yu M, Buczkowicz P, Rakopoulos P, Golbourn B, et al. Poly-ADP-ribose polymerase as a therapeutic target in pediatric diffuse intrinsic pontine glioma and pediatric high-grade astrocytoma. Mol Cancer Ther. 2015;14(11):2560–8.
pubmed: 26351319
doi: 10.1158/1535-7163.MCT-15-0282
Lesueur P, Chevalier F, Austry JB, Waissi W, Burckel H, Noël G, et al. Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies. Oncotarget. 2017;8(40):69105–24.
pubmed: 28978184
pmcid: 5620324
doi: 10.18632/oncotarget.19079
van Vuurden DG, Hulleman E, Meijer OL, Wedekind LE, Kool M, Witt H, et al. PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation. Oncotarget. 2011;2(12):984–96.
pubmed: 22184287
pmcid: 3282104
doi: 10.18632/oncotarget.362
Amsbaugh MJ, Mahajan A, Thall PF, McAleer MF, Paulino AC, Grosshans D, et al. A phase 1/2 trial of reirradiation for diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys. 2019;104(1):144–8.
pubmed: 30610915
doi: 10.1016/j.ijrobp.2018.12.043
Fontanilla HP, Pinnix CC, Ketonen LM, Woo SY, Vats TS, Rytting ME, et al. Palliative reirradiation for progressive diffuse intrinsic pontine glioma. Am J Clin Oncol. 2012;35(1):51–7.
pubmed: 21297433
doi: 10.1097/COC.0b013e318201a2b7
Lassaletta A, Strother D, Laperriere N, Hukin J, Vanan MI, Goddard K, et al. Reirradiation in patients with diffuse intrinsic pontine gliomas: the Canadian experience. Pediatr Blood Cancer. 2018;65(6):e26988.
pubmed: 29369515
doi: 10.1002/pbc.26988
Cacciotti C, Liu KX, Haas-Kogan DA, Warren KE. Reirradiation practices for children with diffuse intrinsic pontine glioma. Neurooncol Pract. 2021;8(1):68–74.
pubmed: 33664971
Fontanilla H, Pinnix C, Ketonen L, et al. Palliative reirradiation for progressive diffuse intrinsic pontine glioma. Am J Clin Oncol. 2012;35(1):51–7.
pubmed: 21297433
doi: 10.1097/COC.0b013e318201a2b7
Massimino M, Biassoni V, Miceli R et al. Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood. J Neurooncol. 2014;118(2):305–12.
pubmed: 24696052
Janssens G, Gandola L, Bolle S et al. Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: a matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group. Eur J Cancer. 2017;73:38–47.
pubmed: 28161497
doi: 10.1016/j.ejca.2016.12.007
Amsbaugh M, Mahajan A, Thall P et al. A phase 1/2 trial of reirradiation for diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys. 2019;104(1):144–8.
doi: 10.1016/j.ijrobp.2018.12.043
Rodriguez D, Calmon R, Aliaga ES, Warren D, Warmuth-Metz M, Jones C, et al. MRI and molecular characterization of pediatric high-grade midline thalamic gliomas: the HERBY Phase II Trial. Radiology. 2022;304(1):174–82.
doi: 10.1148/radiol.211464
Jansen MH, van Vuurden DG, Vandertop WP, Kaspers GJ. Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology. Cancer Treat Rev. 2012;38(1):27–35.
pubmed: 21764221
doi: 10.1016/j.ctrv.2011.06.007
Sanghavi SN, Needle MN, Krailo MD, Geyer JR, Ater J, Mehta MP. A phase I study of topotecan as a radiosensitizer for brainstem glioma of childhood: first report of the Children’s Cancer Group-0952. Neuro Oncol. 2003;5(1):8–13.
pubmed: 12626128
pmcid: 1920667
doi: 10.1093/neuonc/5.1.8
Cohen KJ, Heideman RL, Zhou T, Holmes EJ, Lavey RS, Bouffet E, et al. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. Neuro Oncol. 2011;13(4):410–6.
pubmed: 21345842
pmcid: 3064697
doi: 10.1093/neuonc/noq205
Wagner S, Reinert C, Schmid HJ, Liebeskind AK, Jorch N, Längler A, et al. High-dose methotrexate prior to simultaneous radiochemotherapy in children with malignant high-grade gliomas. Anticancer Res. 2005;25(3c):2583–7.
pubmed: 16080497
Itazaki H, Nagashima K, Sugita K, Yoshida H, Kawamura Y, Yasuda Y, et al. Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents. J Antibiot (Tokyo). 1990;43(12):1524–32.
pubmed: 2276972
doi: 10.7164/antibiotics.43.1524
Sugita K, Koizumi K, Yoshida H. Morphological reversion of sis-transformed NIH3T3 cells by trichostatin A. Cancer Res. 1992;52(1):168–72.
pubmed: 1727377
Medina V, Edmonds B, Young G, James R, Appleton S, Zalewski P. Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res. 1997;57(17):3697–707.
pubmed: 9288776
Leszczynska KB, Jayaprakash C, Kaminska B, Mieczkowski J. Emerging advances in combinatorial treatments of epigenetically altered pediatric high-grade H3K27M gliomas. Front Genet. 2021;12:742561.
pubmed: 34646308
pmcid: 8503186
doi: 10.3389/fgene.2021.742561
Hennika T, Hu G, Olaciregui NG, Barton KL, Ehteda A, Chitranjan A, et al. Pre-clinical study of panobinostat in xenograft and genetically engineered murine diffuse intrinsic pontine glioma models. PloS One. 2017;12(1):e0169485.
pubmed: 28052119
pmcid: 5215670
doi: 10.1371/journal.pone.0169485
Wang ZJ, Ge Y, Altinok D, Poulik J, Sood S, Taub JW, et al. Concomitant use of panobinostat and reirradiation in progressive DIPG: report of 2 cases. J Pediatr Hematol Oncol. 2017;39(6):e332–e5.
pubmed: 28234741
doi: 10.1097/MPH.0000000000000806
Su JM, Kilburn LB, Mansur DB, Krailo M, Buxton A, Adekunle A, et al. Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: a Children’s Oncology Group report. Neuro Oncol. 2022;24(4):655–64.
pubmed: 34347089
doi: 10.1093/neuonc/noab188
Truffaux N, Philippe C, Paulsson J, Andreiuolo F, Guerrini-Rousseau L, Cornilleau G, et al. Preclinical evaluation of dasatinib alone and in combination with cabozantinib for the treatment of diffuse intrinsic pontine glioma. Neuro Oncol. 2015;17(7):953–64.
pubmed: 25534822
doi: 10.1093/neuonc/nou330
Pollack IF, Jakacki RI, Blaney SM, Hancock ML, Kieran MW, Phillips P, et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol. 2007;9(2):145–60.
pubmed: 17293590
pmcid: 1871662
doi: 10.1215/15228517-2006-031
Broniscer A, Baker SD, Wetmore C, Pai Panandiker AS, Huang J, Davidoff AM, et al. Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma. Clin Cancer Res. 2013;19(11):3050–8.
pubmed: 23536435
pmcid: 3685168
doi: 10.1158/1078-0432.CCR-13-0306
Broniscer A, Baker JN, Tagen M, Onar-Thomas A, Gilbertson RJ, Davidoff AM, et al. Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. J Clin Oncol. 2010;28(31):4762–8.
pubmed: 20921456
pmcid: 3020706
doi: 10.1200/JCO.2010.30.3545
Carvalho DM, Richardson PJ, Olaciregui N, Stankunaite R, Lavarino C, Molinari V, et al. Repurposing vandetanib plus everolimus for the treatment of. Cancer Discov. 2022;12(2):416–31.
pubmed: 34551970
doi: 10.1158/2159-8290.CD-20-1201
Geyer JR, Stewart CF, Kocak M, Broniscer A, Phillips P, Douglas JG, et al. A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. Eur J Cancer. 2010;46(18):3287–93.
pubmed: 20708924
pmcid: 2988095
doi: 10.1016/j.ejca.2010.07.005
Geoerger B, Hargrave D, Thomas F, Ndiaye A, Frappaz D, Andreiuolo F, et al. Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro Oncol. 2011;13(1):109–18.
pubmed: 20974795
doi: 10.1093/neuonc/noq141
Grill J, Le Teuff G, Nysom K, Blomgren K, Hargrave D, McCowage G, et al. PDCT-01. Biological medicine for diffuse intrinsic pontine gliomas eradication (Biomede): results of the three-arm biomarker-driveN randomized trial in the first 230 patients from Europe and Australia. Neuro Oncol. 2019;21:vi183. © The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com
pmcid: 6847455
doi: 10.1093/neuonc/noz175.765
Persson ML, Douglas AM, Alvaro F, Faridi P, Larsen MR, Alonso MM, et al. The intrinsic and microenvironmental features of diffuse midline glioma: implications for the development of effective immunotherapeutic treatment strategies. Neuro Oncol. 2022;24(9):1408–22.
pubmed: 35481923
pmcid: 9435509
doi: 10.1093/neuonc/noac117
Becher OJ, Millard NE, Modak S, Kushner BH, Haque S, Spasojevic I, et al. A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors. PloS One. 2017;12(6):e0178593.
pubmed: 28582410
pmcid: 5459446
doi: 10.1371/journal.pone.0178593
Becher OJ, Gilheeney SW, Khakoo Y, Lyden DC, Haque S, De Braganca KC, et al. A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors. Pediatr Blood Cancer. 2017;64(7). https://doi.org/10.1002/pbc.26409 .
Erker C, Lane A, Chaney B, Leary S, Minturn JE, Bartels U, et al. Characteristics of patients ≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. Neuro Oncol. 2022;24(1):141–52.
pubmed: 34114629
doi: 10.1093/neuonc/noab140
Vanan MI, Eisenstat DD. DIPG in children - what can we learn from the past? Front Oncol. 2015;5:237.
pubmed: 26557503
pmcid: 4617108
doi: 10.3389/fonc.2015.00237
Massimino M, Biassoni V, Miceli R, Schiavello E, Warmuth-Metz M, Modena P, et al. Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood. J Neurooncol. 2014;118(2):305–12.
pubmed: 24696052
Fleischhack G, Massimino M, Warmuth-Metz M, Khuhlaeva E, Janssen G, Graf N, et al. Nimotuzumab and radiotherapy for treatment of newly diagnosed diffuse intrinsic pontine glioma (DIPG): a phase III clinical study. J Neurooncol. 2019;143(1):107–13.
pubmed: 30830679
doi: 10.1007/s11060-019-03140-z
Kebudi R, Cakir FB, Bay SB, Gorgun O, Altınok P, Iribas A, et al. Nimotuzumab-containing regimen for pediatric diffuse intrinsic pontine gliomas: a retrospective multicenter study and review of the literature. Childs Nerv Syst. 2019;35(1):83–9.
pubmed: 30417211
doi: 10.1007/s00381-018-4001-9
Parenrengi MA, Suryaningtyas W, Al Fauzi A, Hafid Bajamal A, Kusumastuti K, Utomo B, et al. Nimotuzumab as additional therapy for GLIOMA in pediatric and adolescent: a systematic review. Cancer Control. 2022;29:10732748211053927.
pubmed: 35191733
pmcid: 8874160
doi: 10.1177/10732748211053927
Matthews HK, Bertoli C, de Bruin RAM. Cell cycle control in cancer. Nat Rev Mol Cell Biol. 2022;23(1):74–88.
pubmed: 34508254
doi: 10.1038/s41580-021-00404-3
DeWire M, Fuller C, Hummel TR, Chow LML, Salloum R, de Blank P, et al. A phase I/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). J Neurooncol. 2020;149(3):511–22.
pubmed: 33034839
doi: 10.1007/s11060-020-03641-2
Schüller U, Iglauer P, Dorostkar MM, Mawrin C, Herms J, Giese A, et al. Mutations within FGFR1 are associated with superior outcome in a series of 83 diffuse midline gliomas with H3F3A K27M mutations. Acta Neuropathol. 2021;141(2):323–5.
pubmed: 33433639
pmcid: 7847449
doi: 10.1007/s00401-020-02259-y
Nguyen AT, Colin C, Nanni-Metellus I, Padovani L, Maurage CA, Varlet P, et al. Evidence for BRAF V600E and H3F3A K27M double mutations in paediatric glial and glioneuronal tumours. Neuropathol Appl Neurobiol. 2015;41(3):403–8.
pubmed: 25389051
doi: 10.1111/nan.12196
Solomon DA, Wood MD, Tihan T, Bollen AW, Gupta N, Phillips JJ, et al. Diffuse midline gliomas with histone H3-K27M mutation: a series of 47 cases assessing the spectrum of morphologic variation and associated genetic alterations. Brain Pathol. 2016;26(5):569–80.
pubmed: 26517431
doi: 10.1111/bpa.12336
Joyon N, Tauziède-Espariat A, Alentorn A, Giry M, Castel D, Capelle L, et al. K27M mutation in H3F3A in ganglioglioma grade I with spontaneous malignant transformation extends the histopathological spectrum of the histone H3 oncogenic pathway. Neuropathol Appl Neurobiol. 2017;43(3):271–6.
pubmed: 27219822
doi: 10.1111/nan.12329
Pagès M, Beccaria K, Boddaert N, Saffroy R, Besnard A, Castel D, et al. Co-occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma. Brain Pathol. 2018;28(1):103–11.
pubmed: 27984673
doi: 10.1111/bpa.12473
Ryall S, Zapotocky M, Fukuoka K, Nobre L, Guerreiro Stucklin A, Bennett J, et al. Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas. Cancer Cell. 2020;37(4):569–83.e5.
pubmed: 32289278
pmcid: 7169997
doi: 10.1016/j.ccell.2020.03.011
Blumenthal DT, Yalon M, Vainer GW, Lossos A, Yust S, Tzach L, et al. Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors. J Neurooncol. 2016;129(3):453–60.
pubmed: 27377654
doi: 10.1007/s11060-016-2190-1
Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019;25(3):477–86.
pubmed: 30742122
pmcid: 6408961
doi: 10.1038/s41591-018-0337-7
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–64.
pubmed: 22437870
pmcid: 4856023
doi: 10.1038/nrc3239
Johnson DB, Sullivan RJ, Menzies AM. Immune checkpoint inhibitors in challenging populations. Cancer. 2017;123(11):1904–11.
pubmed: 28241095
doi: 10.1002/cncr.30642
Cacciotti C, Choi J, Alexandrescu S, Zimmerman MA, Cooney TM, Chordas C, et al. Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience. J Neurooncol. 2020;149(1):113–22.
pubmed: 32627129
doi: 10.1007/s11060-020-03578-6
Kline C, Liu SJ, Duriseti S, Banerjee A, Nicolaides T, Raber S, et al. Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience. J Neurooncol. 2018;140(3):629–38.
pubmed: 30206764
doi: 10.1007/s11060-018-2991-5
Hwang E, Onar A, Young-Poussaint T, Mitchell D, Kilburn L, Margol A, et al. IMMU-09.Outcome of patients with recurrent diffuse intrinsic pontine glioma (DIPG) treated with pembrolizumab (anti-PD-1): a pediatric brain tumor consortium study (PBTC045). Neuro Oncol. 2018;20(Suppl 2):i100.
pmcid: 6012545
doi: 10.1093/neuonc/noy059.325
Ochs K, Ott M, Bunse T, Sahm F, Bunse L, Deumelandt K, et al. K27M-mutant histone-3 as a novel target for glioma immunotherapy. Oncoimmunology. 2017;6(7):e1328340.
pmcid: 5543817
doi: 10.1080/2162402X.2017.1328340
Vandenberk L, Belmans J, Van Woensel M, Riva M, Van Gool SW. Exploiting the immunogenic potential of cancer cells for improved dendritic cell vaccines. Front Immunol. 2015;6:663.
pubmed: 26834740
Benitez-Ribas D, Cabezón R, Flórez-Grau G, Molero MC, Puerta P, Guillen A, et al. Immune response generated with the administration of autologous dendritic cells pulsed with an allogenic tumoral cell-lines lysate in patients with newly diagnosed diffuse intrinsic pontine glioma. Front Oncol. 2018;8:127.
pubmed: 29755954
pmcid: 5932163
doi: 10.3389/fonc.2018.00127
Martínez-Vélez N, Garcia-Moure M, Marigil M, González-Huarriz M, Puigdelloses M, Gallego Pérez-Larraya J, et al. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models. Nat Commun. 2019;10(1):2235.
pubmed: 31138805
pmcid: 6538754
doi: 10.1038/s41467-019-10043-0
de Billy E, Pellegrino M, Orlando D, Pericoli G, Ferretti R, Businaro P, et al. Dual IGF1R/IR inhibitors in combination with GD2-CAR T-cells display a potent anti-tumor activity in diffuse midline glioma H3K27M-mutant. Neuro Oncol. 2022;24(7):1150–63.
pubmed: 34964902
doi: 10.1093/neuonc/noab300
Majzner RG, Ramakrishna S, Yeom KW, Patel S, Chinnasamy H, Schultz LM, et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature. 2022;603(7903):934–41.
pubmed: 35130560
pmcid: 8967714
doi: 10.1038/s41586-022-04489-4
Mount CW, Majzner R, Sundaresh S, Arnold EP, Kadapakkam M, Haile S, et al. Abstract 958: Anti-GD2 chimeric antigen receptor T cells as a potent immunotherapy regimen in xenograft models of histone 3 K27M mutant diffuse midline glioma. Cancer Res. 2018;78(13 Supplement):958.
doi: 10.1158/1538-7445.AM2018-958
Mount CW, Majzner RG, Sundaresh S, Arnold EP, Kadapakkam M, Haile S, et al. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas. Nat Med. 2018;24(5):572.
pubmed: 29662203
pmcid: 6214371
doi: 10.1038/s41591-018-0006-x